IMMUTEP
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2001-01-01
- Employees
- -
- Market Cap
- $363.8M
- Website
- http://www.immutep.com/
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
Phase 1
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- Biological: IMP321
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- Immutep S.A.S.
- Target Recruit Count
- 33
- Registration Number
- NCT00349934
- Locations
- 🇫🇷
Centre René Huguenin, Saint-Cloud, France
🇫🇷Hôpital Tenon, Paris, France
🇫🇷Hôpital Européen Georges Pompidou, Paris, France
© Copyright 2025. All Rights Reserved by MedPath